Drug targets for amyloidosis

Biochemical Society Transactions

Volumn 38, Issue 2, 2010, Pages 466-470

  Kolstoe, Simon E ^a   Wood, Steve P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloidosis; C reactive protein (crp); Drug target; Transthyretin (ttr)

Indexed keywords

[1 [6 (2 CARBOXYPYRROLIDIN 1 YL) 6 OXO HEXANOYL]PYRROLIDINE 2 CARBOXYLIC ACID]; AMYLOID BETA PROTEIN; CARBOXYLIC ACID DERIVATIVE; OPSONIN; PREALBUMIN; SERUM AMYLOID P; STABILIZING AGENT; SUPEROXIDE DISMUTASE; THYROXINE; UNCLASSIFIED DRUG; CARBOXYLIC ACID; CROSS LINKING REAGENT; PYRROLIDINE DERIVATIVE; R 1 (6 (R 2 CARBOXYPYRROLIDIN 1 YL) 6 OXOHEXANOYL)PYRROLIDINE 2 CARBOXYLIC ACID; R-1-(6-(R-2-CARBOXYPYRROLIDIN-1-YL)-6-OXOHEXANOYL)PYRROLIDINE-2-CARBOXYLIC ACID;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; CENTRAL NERVOUS SYSTEM; CIRCULATION; CLEARANCE; CLINICAL FEATURE; DEGENERATIVE DISEASE; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; PRIORITY JOURNAL; PROTEIN FOLDING; ANIMAL; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; METHODOLOGY; PHYSIOLOGY; PROTEIN BINDING; PROTEIN MULTIMERIZATION; REVIEW;

ANIMALIA;

AMYLOIDOSIS; ANIMALS; CARBOXYLIC ACIDS; CROSS-LINKING REAGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NEURODEGENERATIVE DISEASES; PREALBUMIN; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PYRROLIDINES; SERUM AMYLOID P-COMPONENT;

EID: 77953251166     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0380466     Document Type: Article

References (34)

1. Kolstoe, S. and Wood, S. (2004) Perspectives for drug intervention in amyloid diseases. Curr. Drug Targets 5, 151-158
2. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F. et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523-527
3. Amijee, H. and Scopes, D.I. (2009) The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. J. Alzheimer's Dis. 17, 33-47
4. Pepys, M.B. (2001) Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos. Trans. R. Soc. London Ser. B 356, 203-210
5. Reixach, N., Deechongkit, S., Jiang, X., Kelly, J.W. and Buxbaum, J.N. (2004) Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. U.S.A. 101, 2817-2822
6. Sousa, M.M., Cardoso, I., Fernandes, R., Guimaraes, A. and Saraiva, M.J. (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159, 1993-2000
7. Pepys, M.B., Booth, D.R., Hutchinson, D.R., Gallimore, J.R., Collins, P.M. and Hohenester, E. (1997) Amyloid P component: a critical review. Amyloid: Int. J. Exp. Clin. Invest. 4, 274-295
8. Pepys, M.B., Herbert, J., Hutchinson, W.L., Tennent, G.A., Lachmann, H.J., Gallimore, J.R., Lovat, L.B., Bartfai, T., Alanine, A., Hertel, C. et al. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259
9. Pepys, M.B. (2006) Amyloidosis. Annu. Rev. Med. 57, 223-241
10. Saraiva, M.J. (2002) Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies. Expert Rev. Mol. Med. 4, 1-11
11. Jacobson, D.R., Pastore, R.D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F.S. and Buxbaum, J.N. (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N. Engl. J. Med. 336, 466-473
12. Blake, C.C., Geisow, M.J., Oatley, S.J., Rerat, B. and Rerat, C. (1978) Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J. Mol. Biol. 121, 339-356
13. Blake, C.C., Swan, I.D., Rerat, C., Berthou, J., Laurent, A. and Rerat, B. (1971) An X-ray study of the subunit structure of prealbumin. J. Mol. Biol. 61, 217-224
14. 30 familial amyloidotic polyneuropathy (FAP) patients: axially arrayed TTR monomers constitute the protofilament. Amyloid 5, 163-174
15. Serag, A.A., Altenbach, C., Gingery, M., Hubbell, W.L. and Yeates, T.O. (2001) Identification of a subunit interface in transthyretin amyloid fibrils: evidence for self-assembly from oligomeric building blocks. Biochemistry 40, 9089-9096
16. Serag, A.A., Altenbach, C., Gingery, M., Hubbell, W.L. and Yeates, T.O. (2002) Arrangement of subunits and ordering of β-strands in an amyloid sheet. Nat. Struct. Biol. 9, 734-739
17. Eneqvist, T., Andersson, K., Olofsson, A., Lundgren, E. and Sauer-Eriksson, A.E. (2000) The β-slip: a novel concept in transthyretin amyloidosis. Mol. Cell 6, 1207-1218
18. Johnson, S.M., Wiseman, R.L., Sekijima, Y., Green, N.S., Adamski-Werner, S.L. and Kelly, J.W. (2005) Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 38, 911-921
19. Hornberg, A., Eneqvist, T., Olofsson, A., Lundgren, E. and Sauer-Eriksson, A.E. (2000) A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J. Mol. Biol. 302, 649-669
20. Reference deleted
21. Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26
22. Purkey, H.E., Dorrell, M.I. and Kelly, J.W. (2001) Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc. Natl. Acad. Sci. U.S.A. 98, 5566-5571
23. Johnson, S.M., Connelly, S., Wilson, I.A. and Kelly, J.W. (2008) Biochemical and structural evaluation of highly selective 2-arylbenzoxazole- based transthyretin amyloidogenesis inhibitors. J. Med. Chem. 51, 260-270
24. Green, N.S., Palaninathan, S.K., Sacchettini, J.C. and Kelly, J.W. (2003) Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. J. Am. Chem. Soc. 125, 13404-13414
25. Cathcart, E.S., Wollheim, F.A. and Cohen, A.S. (1967) Plasma protein constituents of amyloid fibrils. J. Immunol. 99, 376-385
26. Tennent, G.A., Lovat, L.B. and Pepys, M.B. (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 92, 4299-4303
27. Hawkins, P.N. and Pepys, M.B. (1995) Imaging amyloidosis with radiolabelled SAP. Eur. J. Nucl. Med. 22, 595-599
28. Emsley, J., White, H.E., O'Hara, B.P., Oliva, G., Srinivasan, N., Tickle, I.J., Blundell, T.L., Pepys, M.B. and Wood, S.P. (1994) Structure of pentameric human serum amyloid P component. Nature 367, 338-345
29. Yasojima, K., Schwab, C., McGeer, E.G. and McGeer, P.L. (2000) Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 887, 80-89
30. Hutchinson, W.L., Hohenester, E. and Pepys, M.B. (2000) Human serum amyloid P component is a single uncomplexed pentamer in whole serum. Mol. Med. 6, 482-493
31. Shirahama, T. and Cohen, A.S. (1967) High-resolution electron microscopic analysis of the amyloid fibril. J. Cell Biol. 33, 679-708
32. Pinteric, L. and Painter, R.H. (1979) Electron microscopy of serum amyloid protein in the presence of calcium: alternative forms of assembly of pentagonal molecules in two-dimensional lattices. Can. J. Biochem. 57, 727-736
33. Kolstoe, S.E., Ridha, B.H., Bellotti, V., Wang, N., Robinson, C.V., Crutch, S.J., Keir, G., Kukkastenvehmas, R., Gallimore, J.R., Hutchinson, W.L. et al. (2009) Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc. Natl. Acad. Sci. U.S.A. 106, 7619-7623
34. Costa, R., Goncalves, A., Saraiva, M.J. and Cardoso, I. (2008) Transthyretin binding to A-β peptide: impact on A-β fibrillogenesis and toxicity. FEBS Lett. 582, 936-942